Navigation Links
Mouse model highlights histone methylation as distinguishing feature for leukemia subtypes
Date:11/3/2008

Research using a new mouse model has led to the identification of a potential therapeutic target for a type of leukemia commonly associated with an unfavorable prognosis. The study, published by Cell Press in the November issue of the journal Cancer Cell, also validates examination of histone modification as a strategy for distinguishing cancer subtypes.

MLL rearrangements have been observed in some cases of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ALL patients with rearranged MLL have a relatively poor prognosis when compared with patients who have other types of ALL. Although several mouse models of MML-rearranged AML, modeling MLL-rearranges ALL has proven difficult. Recent studies have suggested that some MLL fusion proteins enhance gene expression by recruiting the histone H3 lysine79 (H3K79) methytransferase, DOT1L. Addition of a methyl group to histones plays an important regulatory role in the control of gene expression and is an example of an epigenetic change, a chemical alteration that does not change the DNA sequence.

"Aberrant recruitment of DOT1L to the promoters of MLL target genes may be a common feature of many oncogenic MLL fusion proteins. However, the extent of H3K79 methylation changes and the specificity of these epigenetic changes for MLL-rearranged leukemias have not been defined," says senior study author Dr. Scott A. Armstrong from the Dana-Farber Cancer Institute, Children's Hospital and Harvard Medical School.

Dr. Armstrong and colleagues created a mouse model in which conditional expression of MLL-AF4 induced both ALL and AML. They demonstrated that their model faithfully recapitulated human ALL resulting from MLL-AF4 translocation and identified a critical role for H3K79 methylation in MLL-AF4-driven gene expression and transformation. Importantly, suppression of DOT1L resulted in a reduction of methylated H3K79 and expression of critical MLL-AF4 target genes. "Our findings support the inhibition of DOT1L as a potential therapeutic approach in this disease and that this mouse model should be useful for assessment of therapeutic approaches for MLL-rearranged ALL," offers Dr. Armstrong.

"Our study also demonstrates that widespread differences in an epigenetic histone modification can distinguish different cancer subtypes and malignant versus normal cells," explains Dr. Armstrong. "Inasmuch as epigenetic modifications are likely to be linked to the maintenance of gene expression in many human malignancies, these strategies may be applicable to a wide variety of cancer subtypes."


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Mutant Mouse Gene Offers Clues to Hearing Loss
2. Mouse Study Finds Molecule That Tells Hair to Grow
3. Tumor suppressor genes speed up and slow down aging in engineered mouse
4. Mouse Skin Cells Reprogrammed to Act Like Embryonic Stem Cells
5. Mouse Adult Stem Cells Developed into Heart and Blood Cells
6. Mature Mouse Cells Reprogrammed to Stem Cell-Like State
7. Boston College biologists build a better mouse model for cancer research
8. Mouse model for mesothelioma reproduces human disease
9. Mouse study: Real-time imaging device may improve surgery for congenital colon disease
10. Seal Shield Introduces New Silver Seal Washable, Antimicrobial Mouse at HiMSS Healthcare Symposium
11. Mouse Model of Age-Related Macular Degeneration Developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... and high-level training standards for healthcare treatment providers who treat the full spectrum ... Presidents Council. , The Presidents Council consists of the leading eating disorder ...
(Date:1/23/2017)... ... , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of ... making new water infrastructure a number one priority. “As we usher in a new ... to become a top priority of our new political change agents.” Kleyne pointed out ...
(Date:1/23/2017)... ... ... METTLER TOLEDO has announced the availability of a new ... . , Crystallization is a common step used during the synthesis ... spend more time developing better intermediate and final crystallization steps. By adopting ...
(Date:1/23/2017)... Aliso Viejo, California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set ... shaky camera to create dynamic looks in Final Cut Pro X," said Christina Austin - ... movement of up to two layers of text with video footage. ProRandom works by ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Jan. 23, 2017  Using Astute Medical,s ... risk for acute kidney injury (AKI) after open-heart ... care guidelines significantly improved outcomes by ... more than 33 percent, according to a ... Intensive Care Medicine. Experience ...
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries ... technologies. BCC Research reveals in its new report that markets ... should see strong growth due to rising government healthcare spending, increased levels ... Continue Reading ... ...
(Date:1/23/2017)... 2017 NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical collaboration agreement with the Children,s Hospital of ... M.D., a US key opinion leader in the mitochondrial medicine ... ... from NeuroVive,s research program, NVP015, in certain experimental disease models. ...
Breaking Medicine Technology: